• Je něco špatně v tomto záznamu ?

Inhibitory immune checkpoint molecules and exhaustion of T cells in COVID-19

M. Barnova, A. Bobcakova, V. Urdova, R. Kosturiak, L. Kapustova, D. Dobrota, M. Jesenak

. 2021 ; 70 (S2) : S227-S247. [pub] 20211216

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22000862

COVID-19 (Coronavirus Disease) is an infectious disease caused by the coronavirus SARS-CoV-2 (Severe acute respiratory syndrome Coronavirus 2), which belongs to the genus Betacoronavirus. It was first identified in patients with severe respiratory disease in December 2019 in Wuhan, China. It mainly affects the respiratory system, and in severe cases causes serious lung infection or pneumonia, which can lead to the death of the patient. Clinical studies show that SARS-CoV-2 infection in critical cases causes acute tissue damage due to a pathological immune response. The immune response to a new coronavirus is complex and involves many processes of specific and non-specific immunity. Analysis of available studies has shown various changes, especially in the area of specific cellular immunity, including lymphopenia, decreased T cells (CD3+, CD4+ and CD8+), changes in the T cell compartment associated with symptom progression, deterioration of the condition and development of lung damage. We provide a detailed review of the analyses of immune checkpoint molecules PD-1, TIM-3, LAG-3 CTLA-4, TIGIT, BTLA, CD223, IDO-1 and VISTA on exhausted T cells in patients with asymptomatic to symptomatic stages of COVID-19 infection. Furthermore, this review may help to better understand the pathological T cell immune response and improve the design of therapeutic strategies for patients with SARS-CoV-2 infection.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22000862
003      
CZ-PrNML
005      
20220217135130.0
007      
ta
008      
220106s2021 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.934757 $2 doi
035    __
$a (PubMed)34913354
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Barnová, Martina, $d 1993- $7 xx0268411 $u Department of Clinical Immunology and Allergology, University Hospital in Martin, Martin, Slovak Republic
245    10
$a Inhibitory immune checkpoint molecules and exhaustion of T cells in COVID-19 / $c M. Barnova, A. Bobcakova, V. Urdova, R. Kosturiak, L. Kapustova, D. Dobrota, M. Jesenak
504    __
$a Literatura
520    9_
$a COVID-19 (Coronavirus Disease) is an infectious disease caused by the coronavirus SARS-CoV-2 (Severe acute respiratory syndrome Coronavirus 2), which belongs to the genus Betacoronavirus. It was first identified in patients with severe respiratory disease in December 2019 in Wuhan, China. It mainly affects the respiratory system, and in severe cases causes serious lung infection or pneumonia, which can lead to the death of the patient. Clinical studies show that SARS-CoV-2 infection in critical cases causes acute tissue damage due to a pathological immune response. The immune response to a new coronavirus is complex and involves many processes of specific and non-specific immunity. Analysis of available studies has shown various changes, especially in the area of specific cellular immunity, including lymphopenia, decreased T cells (CD3+, CD4+ and CD8+), changes in the T cell compartment associated with symptom progression, deterioration of the condition and development of lung damage. We provide a detailed review of the analyses of immune checkpoint molecules PD-1, TIM-3, LAG-3 CTLA-4, TIGIT, BTLA, CD223, IDO-1 and VISTA on exhausted T cells in patients with asymptomatic to symptomatic stages of COVID-19 infection. Furthermore, this review may help to better understand the pathological T cell immune response and improve the design of therapeutic strategies for patients with SARS-CoV-2 infection.
650    _2
$a zvířata $7 D000818
650    _2
$a COVID-19 $x imunologie $x metabolismus $x virologie $7 D000086382
650    _2
$a interakce hostitele a patogenu $7 D054884
650    _2
$a lidé $7 D006801
650    _2
$a proteiny kontrolních bodů imunitní reakce $x metabolismus $7 D000082102
650    _2
$a fenotyp $7 D010641
650    _2
$a SARS-CoV-2 $x imunologie $x patogenita $7 D000086402
650    _2
$a signální transdukce $7 D015398
650    _2
$a T-lymfocyty $x imunologie $x metabolismus $7 D013601
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bobčáková, Anna $7 xx0231058 $u Centre for Primary Immunodeficiencies, Clinic of Pneumology and Phthisiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovak Republic
700    1_
$a Urdová Dobšinská, Veronika $7 xx0267488 $u Centre for Primary Immunodeficiencies, Clinic of Pneumology and Phthisiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovak Republic $u Second Clinic of Internal Medicine, Slovak Medical University, Faculty Teaching Hospital of F.D. Roosevelt, Banska Bystrica, Slovak Republic
700    1_
$a Košturiak, Radovan $7 xx0231024 $u Out-patient Department of Clinical Immunology and Allergology LEKARTIN, Nitra, Slovak Republic
700    1_
$a Kapustová, Lenka $7 xx0238227 $u Centre for Primary Immunodeficiencies, Clinic of Pediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovak Republic
700    1_
$a Dobrota, Dušan $7 xx0062267 $u Department of Clinical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovak Republic $u Institute of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic
700    1_
$a Jeseňák, Miloš, $d 1980- $7 xx0104191 $u Department of Clinical Immunology and Allergology, University Hospital in Martin, Martin, Slovak Republic $u Centre for Primary Immunodeficiencies, Clinic of Pneumology and Phthisiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovak Republic $u Centre for Primary Immunodeficiencies, Clinic of Pediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital in Martin, Martin, Slovak Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 70, Suppl. 2 (2021), s. S227-S247
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34913354 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20220106 $b ABA008
991    __
$a 20220217135123 $b ABA008
999    __
$a ok $b bmc $g 1761109 $s 1152008
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 70 $c S2 $d S227-S247 $e 20211216 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20220106

Najít záznam

Citační ukazatele

Možnosti archivace